SCHEMBL7665147

SCHEMBL7665147

O=C(Nc1ccc(S(=O)(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)OCc2ccccc2)cc1)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 7/20 0.71
CTSL P07711 2/20 0.56
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
BACE1 P56817 1/20 0.52
ITGB3 P05106 1/20 0.52
ITGB1 P05556 1/20 0.52
ITGAV P06756 1/20 0.52
ITGA2B P08514 1/20 0.52
ITGB5 P18084 1/20 0.52
F2 P00734 2/20 0.51
PRSS1 P07477 2/20 0.51
PRSS2 P07478 2/20 0.51
PRSS3 P35030 2/20 0.51
MMP2 P08253 5/20 0.50
CTSS P25774 1/20 0.50
ADAMTS4 O75173 1/20 0.49
ADRB2 P07550 1/20 0.49
ADRB1 P08588 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7663396 1.00 MMP9 (0.71) MMP9CTSLMEN1KMT2AL3MBTL1
SCHEMBL7670535 0.88 MMP9 (0.87) MMP9MEN1KMT2AL3MBTL1ITGB3
SCHEMBL7673966 0.88 MMP9 (0.87) MMP9MEN1KMT2AL3MBTL1ITGB3
SCHEMBL30689128 0.84 CTSL (0.63) MMP9CTSLMEN1KMT2AL3MBTL1
SCHEMBL7675244 0.84 MMP9 (1.00) MMP9ITGB3ITGB1ITGAVITGA2B
SCHEMBL7668862 0.84 MMP9 (1.00) MMP9ITGB3ITGB1ITGAVITGA2B
SCHEMBL14191412 0.83 MMP9 (0.74) MMP9CTSLMMP2ADAMTS4USP30
SCHEMBL7665251 0.82 MMP9 (0.72) MMP9CTSLMEN1KMT2AITGB3
SCHEMBL7669215 0.82 MMP9 (0.72) MMP9CTSLMEN1KMT2AITGB3
SCHEMBL7671736 0.82 MMP9 (0.57) MMP9CTSLMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed